nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.125	0.163	CbGbCtD
Regorafenib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0626	0.0813	CbGbCtD
Regorafenib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0597	0.0775	CbGbCtD
Regorafenib—ABCG2—Methotrexate—ankylosing spondylitis	0.0503	0.0654	CbGbCtD
Regorafenib—CYP2C19—Prednisone—ankylosing spondylitis	0.0448	0.0582	CbGbCtD
Regorafenib—CYP2B6—Dexamethasone—ankylosing spondylitis	0.044	0.0572	CbGbCtD
Regorafenib—ABCB1—Betamethasone—ankylosing spondylitis	0.0388	0.0504	CbGbCtD
Regorafenib—ABCB1—Prednisolone—ankylosing spondylitis	0.0383	0.0497	CbGbCtD
Regorafenib—ABCB1—Prednisone—ankylosing spondylitis	0.0361	0.047	CbGbCtD
Regorafenib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0357	0.0465	CbGbCtD
Regorafenib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0333	0.0433	CbGbCtD
Regorafenib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.028	0.0363	CbGbCtD
Regorafenib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0271	0.0352	CbGbCtD
Regorafenib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0233	0.0302	CbGbCtD
Regorafenib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0232	0.0302	CbGbCtD
Regorafenib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0229	0.0298	CbGbCtD
Regorafenib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0226	0.0293	CbGbCtD
Regorafenib—CYP3A4—Prednisone—ankylosing spondylitis	0.0217	0.0281	CbGbCtD
Regorafenib—ABCB1—Methotrexate—ankylosing spondylitis	0.0181	0.0236	CbGbCtD
Regorafenib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0135	0.0176	CbGbCtD
Regorafenib—Infarction—Methylprednisolone—ankylosing spondylitis	0.00327	0.0474	CcSEcCtD
Regorafenib—Lymphopenia—Prednisone—ankylosing spondylitis	0.00141	0.0204	CcSEcCtD
Regorafenib—Hypothyroidism—Prednisone—ankylosing spondylitis	0.00112	0.0162	CcSEcCtD
Regorafenib—Mucosal inflammation—Methotrexate—ankylosing spondylitis	0.00109	0.0157	CcSEcCtD
Regorafenib—Polyp—Methotrexate—ankylosing spondylitis	0.000989	0.0143	CcSEcCtD
Regorafenib—Nail disorder—Methotrexate—ankylosing spondylitis	0.000927	0.0134	CcSEcCtD
Regorafenib—Cyst—Methotrexate—ankylosing spondylitis	0.0009	0.013	CcSEcCtD
Regorafenib—Endocrine disorder—Prednisone—ankylosing spondylitis	0.000868	0.0126	CcSEcCtD
Regorafenib—Hepatotoxicity—Methotrexate—ankylosing spondylitis	0.000779	0.0113	CcSEcCtD
Regorafenib—Proteinuria—Methotrexate—ankylosing spondylitis	0.000685	0.00991	CcSEcCtD
Regorafenib—Protein urine present—Methotrexate—ankylosing spondylitis	0.000675	0.00977	CcSEcCtD
Regorafenib—Musculoskeletal stiffness—Methotrexate—ankylosing spondylitis	0.00067	0.0097	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Methotrexate—ankylosing spondylitis	0.000661	0.00957	CcSEcCtD
Regorafenib—Dry skin—Prednisolone—ankylosing spondylitis	0.000659	0.00954	CcSEcCtD
Regorafenib—Hyperuricaemia—Methotrexate—ankylosing spondylitis	0.000648	0.00938	CcSEcCtD
Regorafenib—Blood uric acid increased—Methotrexate—ankylosing spondylitis	0.000612	0.00886	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000582	0.00842	CcSEcCtD
Regorafenib—Dry skin—Betamethasone—ankylosing spondylitis	0.00055	0.00796	CcSEcCtD
Regorafenib—Dry skin—Dexamethasone—ankylosing spondylitis	0.00055	0.00796	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000546	0.0079	CcSEcCtD
Regorafenib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.000546	0.0079	CcSEcCtD
Regorafenib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.000546	0.0079	CcSEcCtD
Regorafenib—Neoplasm—Methotrexate—ankylosing spondylitis	0.000544	0.00787	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000543	0.00786	CcSEcCtD
Regorafenib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000508	0.00736	CcSEcCtD
Regorafenib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000508	0.00736	CcSEcCtD
Regorafenib—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000502	0.00727	CcSEcCtD
Regorafenib—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000501	0.00725	CcSEcCtD
Regorafenib—Haemoglobin—Prednisolone—ankylosing spondylitis	0.0005	0.00723	CcSEcCtD
Regorafenib—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.000499	0.00723	CcSEcCtD
Regorafenib—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.000498	0.00721	CcSEcCtD
Regorafenib—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000497	0.0072	CcSEcCtD
Regorafenib—Dry skin—Prednisone—ankylosing spondylitis	0.000479	0.00693	CcSEcCtD
Regorafenib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000475	0.00688	CcSEcCtD
Regorafenib—Weight decreased—Betamethasone—ankylosing spondylitis	0.000469	0.00679	CcSEcCtD
Regorafenib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000469	0.00679	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000461	0.00667	CcSEcCtD
Regorafenib—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.00046	0.00665	CcSEcCtD
Regorafenib—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000459	0.00664	CcSEcCtD
Regorafenib—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.000457	0.00662	CcSEcCtD
Regorafenib—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000456	0.0066	CcSEcCtD
Regorafenib—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000456	0.00659	CcSEcCtD
Regorafenib—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000456	0.00659	CcSEcCtD
Regorafenib—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.000453	0.00656	CcSEcCtD
Regorafenib—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.000453	0.00656	CcSEcCtD
Regorafenib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000448	0.00649	CcSEcCtD
Regorafenib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000424	0.00613	CcSEcCtD
Regorafenib—Neutropenia—Prednisone—ankylosing spondylitis	0.000422	0.00611	CcSEcCtD
Regorafenib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000417	0.00604	CcSEcCtD
Regorafenib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000417	0.00604	CcSEcCtD
Regorafenib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000415	0.00601	CcSEcCtD
Regorafenib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000415	0.00601	CcSEcCtD
Regorafenib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000414	0.00599	CcSEcCtD
Regorafenib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000411	0.00595	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—ankylosing spondylitis	0.000408	0.00591	CcSEcCtD
Regorafenib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000397	0.00575	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000397	0.00574	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—ankylosing spondylitis	0.000395	0.00571	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000393	0.00569	CcSEcCtD
Regorafenib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000377	0.00545	CcSEcCtD
Regorafenib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000377	0.00545	CcSEcCtD
Regorafenib—Hypertension—Prednisolone—ankylosing spondylitis	0.000374	0.00541	CcSEcCtD
Regorafenib—Alopecia—Betamethasone—ankylosing spondylitis	0.000367	0.00531	CcSEcCtD
Regorafenib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000367	0.00531	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000363	0.00526	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000361	0.00523	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000355	0.00514	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000353	0.00511	CcSEcCtD
Regorafenib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000344	0.00497	CcSEcCtD
Regorafenib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000343	0.00496	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000336	0.00487	CcSEcCtD
Regorafenib—Infestation—Methotrexate—ankylosing spondylitis	0.000336	0.00487	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000336	0.00486	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000334	0.00483	CcSEcCtD
Regorafenib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000332	0.0048	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000328	0.00475	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—ankylosing spondylitis	0.000328	0.00475	CcSEcCtD
Regorafenib—Infection—Triamcinolone—ankylosing spondylitis	0.000323	0.00467	CcSEcCtD
Regorafenib—Infection—Methylprednisolone—ankylosing spondylitis	0.000322	0.00466	CcSEcCtD
Regorafenib—Alopecia—Prednisone—ankylosing spondylitis	0.000319	0.00462	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000318	0.0046	CcSEcCtD
Regorafenib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000318	0.0046	CcSEcCtD
Regorafenib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000315	0.00456	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—ankylosing spondylitis	0.000315	0.00455	CcSEcCtD
Regorafenib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000312	0.00451	CcSEcCtD
Regorafenib—Hypertension—Betamethasone—ankylosing spondylitis	0.000312	0.00451	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000304	0.00439	CcSEcCtD
Regorafenib—Pain—Prednisolone—ankylosing spondylitis	0.000302	0.00437	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000302	0.00437	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000298	0.00432	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000296	0.00428	CcSEcCtD
Regorafenib—Infection—Dexamethasone—ankylosing spondylitis	0.000293	0.00424	CcSEcCtD
Regorafenib—Infection—Betamethasone—ankylosing spondylitis	0.000293	0.00424	CcSEcCtD
Regorafenib—Anaemia—Prednisone—ankylosing spondylitis	0.000291	0.00421	CcSEcCtD
Regorafenib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000289	0.00418	CcSEcCtD
Regorafenib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000289	0.00418	CcSEcCtD
Regorafenib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000289	0.00418	CcSEcCtD
Regorafenib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000289	0.00418	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000286	0.00413	CcSEcCtD
Regorafenib—RAF1—Innate Immune System—CARD9—ankylosing spondylitis	0.000284	0.00176	CbGpPWpGaD
Regorafenib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00028	0.00406	CcSEcCtD
Regorafenib—Fatigue—Triamcinolone—ankylosing spondylitis	0.00028	0.00405	CcSEcCtD
Regorafenib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00028	0.00405	CcSEcCtD
Regorafenib—MAPK11—Immune System—IL1R2—ankylosing spondylitis	0.000278	0.00172	CbGpPWpGaD
Regorafenib—Pain—Triamcinolone—ankylosing spondylitis	0.000278	0.00402	CcSEcCtD
Regorafenib—RAF1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000277	0.00171	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000276	0.00171	CbGpPWpGaD
Regorafenib—FGFR1—Disease—ANTXR2—ankylosing spondylitis	0.000275	0.0017	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—ANTXR2—ankylosing spondylitis	0.000274	0.0017	CbGpPWpGaD
Regorafenib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000274	0.00397	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000272	0.00394	CcSEcCtD
Regorafenib—Hypertension—Prednisone—ankylosing spondylitis	0.000272	0.00393	CcSEcCtD
Regorafenib—RAF1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000272	0.00168	CbGpPWpGaD
Regorafenib—Alopecia—Methotrexate—ankylosing spondylitis	0.000267	0.00386	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000266	0.00385	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000265	0.00384	CcSEcCtD
Regorafenib—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000264	0.00164	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—ERAP1—ankylosing spondylitis	0.000264	0.00163	CbGpPWpGaD
Regorafenib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000263	0.00381	CcSEcCtD
Regorafenib—MAPK11—Innate Immune System—HLA-C—ankylosing spondylitis	0.00026	0.00161	CbGpPWpGaD
Regorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.00026	0.00161	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000258	0.0016	CbGpPWpGaD
Regorafenib—PDGFRA—Allograft Rejection—TNF—ankylosing spondylitis	0.000258	0.0016	CbGpPWpGaD
Regorafenib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000257	0.00372	CcSEcCtD
Regorafenib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000257	0.00159	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000257	0.00159	CbGpPWpGaD
Regorafenib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000256	0.00371	CcSEcCtD
Regorafenib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000256	0.00371	CcSEcCtD
Regorafenib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000256	0.00371	CcSEcCtD
Regorafenib—FGFR2—Immune System—IL1R2—ankylosing spondylitis	0.000256	0.00158	CbGpPWpGaD
Regorafenib—Infection—Prednisone—ankylosing spondylitis	0.000255	0.00369	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000255	0.00368	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000255	0.00368	CcSEcCtD
Regorafenib—Fatigue—Betamethasone—ankylosing spondylitis	0.000254	0.00368	CcSEcCtD
Regorafenib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000254	0.00368	CcSEcCtD
Regorafenib—Pain—Betamethasone—ankylosing spondylitis	0.000252	0.00365	CcSEcCtD
Regorafenib—Pain—Dexamethasone—ankylosing spondylitis	0.000252	0.00365	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000252	0.00364	CcSEcCtD
Regorafenib—KIT—Immune System—IL1R2—ankylosing spondylitis	0.000251	0.00155	CbGpPWpGaD
Regorafenib—Skin disorder—Prednisone—ankylosing spondylitis	0.000249	0.00361	CcSEcCtD
Regorafenib—PDGFRB—Disease—ANTXR2—ankylosing spondylitis	0.000247	0.00153	CbGpPWpGaD
Regorafenib—MAPK11—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000246	0.00153	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000245	0.00152	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000244	0.00151	CbGpPWpGaD
Regorafenib—Anaemia—Methotrexate—ankylosing spondylitis	0.000243	0.00352	CcSEcCtD
Regorafenib—FGFR2—Immune System—ERAP1—ankylosing spondylitis	0.000242	0.0015	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CARD9—ankylosing spondylitis	0.000241	0.00149	CbGpPWpGaD
Regorafenib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000241	0.00349	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000241	0.00349	CcSEcCtD
Regorafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000239	0.00148	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000239	0.00148	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1R2—ankylosing spondylitis	0.000238	0.00148	CbGpPWpGaD
Regorafenib—KIT—Immune System—ERAP1—ankylosing spondylitis	0.000238	0.00147	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1R2—ankylosing spondylitis	0.000238	0.00147	CbGpPWpGaD
Regorafenib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000235	0.00341	CcSEcCtD
Regorafenib—KIT—Innate Immune System—HLA-C—ankylosing spondylitis	0.000235	0.00145	CbGpPWpGaD
Regorafenib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000233	0.00337	CcSEcCtD
Regorafenib—FGFR2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000229	0.00142	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000226	0.0014	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—ERAP1—ankylosing spondylitis	0.000226	0.0014	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000225	0.0014	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—ERAP1—ankylosing spondylitis	0.000225	0.00139	CbGpPWpGaD
Regorafenib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000223	0.00323	CcSEcCtD
Regorafenib—Rash—Prednisolone—ankylosing spondylitis	0.000223	0.00322	CcSEcCtD
Regorafenib—FGFR1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000223	0.00138	CbGpPWpGaD
Regorafenib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000223	0.00322	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000222	0.00322	CcSEcCtD
Regorafenib—PDGFRA—Innate Immune System—HLA-C—ankylosing spondylitis	0.000222	0.00138	CbGpPWpGaD
Regorafenib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000222	0.00321	CcSEcCtD
Regorafenib—FGFR2—Immune System—CARD9—ankylosing spondylitis	0.000222	0.00137	CbGpPWpGaD
Regorafenib—Fatigue—Prednisone—ankylosing spondylitis	0.000221	0.0032	CcSEcCtD
Regorafenib—Headache—Prednisolone—ankylosing spondylitis	0.000221	0.0032	CcSEcCtD
Regorafenib—RAF1—Disease—ANTXR2—ankylosing spondylitis	0.00022	0.00136	CbGpPWpGaD
Regorafenib—KIT—Immune System—CARD9—ankylosing spondylitis	0.000218	0.00135	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1R2—ankylosing spondylitis	0.000214	0.00133	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000214	0.00132	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000213	0.00132	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000213	0.00132	CbGpPWpGaD
Regorafenib—Infection—Methotrexate—ankylosing spondylitis	0.000213	0.00309	CcSEcCtD
Regorafenib—Asthenia—Betamethasone—ankylosing spondylitis	0.000212	0.00306	CcSEcCtD
Regorafenib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000212	0.00306	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00021	0.00305	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.00021	0.00304	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00021	0.00304	CcSEcCtD
Regorafenib—Nausea—Prednisolone—ankylosing spondylitis	0.00021	0.00304	CcSEcCtD
Regorafenib—ABL1—Immune System—IL1R2—ankylosing spondylitis	0.000209	0.00129	CbGpPWpGaD
Regorafenib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000208	0.00302	CcSEcCtD
Regorafenib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000207	0.00299	CcSEcCtD
Regorafenib—FGFR1—Immune System—CARD9—ankylosing spondylitis	0.000207	0.00128	CbGpPWpGaD
Regorafenib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000206	0.00298	CcSEcCtD
Regorafenib—PDGFRA—Immune System—CARD9—ankylosing spondylitis	0.000206	0.00128	CbGpPWpGaD
Regorafenib—Rash—Triamcinolone—ankylosing spondylitis	0.000205	0.00296	CcSEcCtD
Regorafenib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000205	0.00296	CcSEcCtD
Regorafenib—Rash—Methylprednisolone—ankylosing spondylitis	0.000204	0.00296	CcSEcCtD
Regorafenib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000204	0.00296	CcSEcCtD
Regorafenib—Headache—Triamcinolone—ankylosing spondylitis	0.000204	0.00295	CcSEcCtD
Regorafenib—NTRK1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000203	0.00126	CbGpPWpGaD
Regorafenib—Headache—Methylprednisolone—ankylosing spondylitis	0.000203	0.00294	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000203	0.00294	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000203	0.00294	CcSEcCtD
Regorafenib—PDGFRB—Immune System—ERAP1—ankylosing spondylitis	0.000203	0.00126	CbGpPWpGaD
Regorafenib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000202	0.00292	CcSEcCtD
Regorafenib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000202	0.00292	CcSEcCtD
Regorafenib—PDGFRB—Innate Immune System—HLA-C—ankylosing spondylitis	0.0002	0.00124	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000199	0.00123	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ERAP1—ankylosing spondylitis	0.000198	0.00122	CbGpPWpGaD
Regorafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000197	0.00122	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000195	0.00121	CbGpPWpGaD
Regorafenib—Nausea—Triamcinolone—ankylosing spondylitis	0.000193	0.00279	CcSEcCtD
Regorafenib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000193	0.00279	CcSEcCtD
Regorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000192	0.00119	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000192	0.00119	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1R2—ankylosing spondylitis	0.000191	0.00118	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000188	0.00116	CbGpPWpGaD
Regorafenib—BRAF—Disease—B3GNT2—ankylosing spondylitis	0.000188	0.00116	CbGpPWpGaD
Regorafenib—Vomiting—Betamethasone—ankylosing spondylitis	0.000187	0.00271	CcSEcCtD
Regorafenib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000187	0.00271	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000187	0.0027	CcSEcCtD
Regorafenib—Rash—Betamethasone—ankylosing spondylitis	0.000186	0.00269	CcSEcCtD
Regorafenib—Rash—Dexamethasone—ankylosing spondylitis	0.000186	0.00269	CcSEcCtD
Regorafenib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000186	0.00269	CcSEcCtD
Regorafenib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000186	0.00269	CcSEcCtD
Regorafenib—PDGFRB—Immune System—CARD9—ankylosing spondylitis	0.000186	0.00115	CbGpPWpGaD
Regorafenib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000185	0.00268	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—ankylosing spondylitis	0.000185	0.00268	CcSEcCtD
Regorafenib—Headache—Betamethasone—ankylosing spondylitis	0.000185	0.00267	CcSEcCtD
Regorafenib—Headache—Dexamethasone—ankylosing spondylitis	0.000185	0.00267	CcSEcCtD
Regorafenib—Asthenia—Prednisone—ankylosing spondylitis	0.000184	0.00267	CcSEcCtD
Regorafenib—NTRK1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000184	0.00114	CbGpPWpGaD
Regorafenib—Pain—Methotrexate—ankylosing spondylitis	0.000184	0.00266	CcSEcCtD
Regorafenib—RAF1—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000183	0.00114	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CARD9—ankylosing spondylitis	0.000181	0.00112	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ERAP1—ankylosing spondylitis	0.000181	0.00112	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000178	0.0011	CbGpPWpGaD
Regorafenib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000176	0.00254	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000175	0.00254	CcSEcCtD
Regorafenib—Nausea—Betamethasone—ankylosing spondylitis	0.000175	0.00253	CcSEcCtD
Regorafenib—Nausea—Dexamethasone—ankylosing spondylitis	0.000175	0.00253	CcSEcCtD
Regorafenib—FGFR2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000175	0.00108	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000174	0.00108	CbGpPWpGaD
Regorafenib—FGFR2—Disease—B3GNT2—ankylosing spondylitis	0.000174	0.00108	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000172	0.00106	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000171	0.00106	CbGpPWpGaD
Regorafenib—KIT—Disease—B3GNT2—ankylosing spondylitis	0.000171	0.00106	CbGpPWpGaD
Regorafenib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00017	0.00245	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00017	0.00245	CcSEcCtD
Regorafenib—RAF1—Immune System—CARD9—ankylosing spondylitis	0.000165	0.00102	CbGpPWpGaD
Regorafenib—BRAF—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000164	0.00101	CbGpPWpGaD
Regorafenib—Vomiting—Prednisone—ankylosing spondylitis	0.000163	0.00236	CcSEcCtD
Regorafenib—FGFR1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000163	0.00101	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000163	0.00101	CbGpPWpGaD
Regorafenib—FGFR1—Disease—B3GNT2—ankylosing spondylitis	0.000162	0.001	CbGpPWpGaD
Regorafenib—Rash—Prednisone—ankylosing spondylitis	0.000162	0.00234	CcSEcCtD
Regorafenib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	0.000162	0.001	CbGpPWpGaD
Regorafenib—Dermatitis—Prednisone—ankylosing spondylitis	0.000162	0.00234	CcSEcCtD
Regorafenib—Headache—Prednisone—ankylosing spondylitis	0.000161	0.00233	CcSEcCtD
Regorafenib—FLT1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000159	0.000985	CbGpPWpGaD
Regorafenib—Asthenia—Methotrexate—ankylosing spondylitis	0.000154	0.00223	CcSEcCtD
Regorafenib—MAPK11—Innate Immune System—HLA-B—ankylosing spondylitis	0.000154	0.000953	CbGpPWpGaD
Regorafenib—Nausea—Prednisone—ankylosing spondylitis	0.000153	0.00221	CcSEcCtD
Regorafenib—FLT4—Signaling Pathways—MMP3—ankylosing spondylitis	0.000152	0.00094	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-C—ankylosing spondylitis	0.000152	0.000939	CbGpPWpGaD
Regorafenib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000147	0.00212	CcSEcCtD
Regorafenib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000147	0.000908	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	0.000146	0.000902	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000143	0.000883	CbGpPWpGaD
Regorafenib—FGFR1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000141	0.000876	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000141	0.000875	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00014	0.000868	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-C—ankylosing spondylitis	0.000139	0.000862	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	0.000139	0.000859	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-C—ankylosing spondylitis	0.000137	0.000846	CbGpPWpGaD
Regorafenib—Vomiting—Methotrexate—ankylosing spondylitis	0.000136	0.00197	CcSEcCtD
Regorafenib—MAPK11—Innate Immune System—CRP—ankylosing spondylitis	0.000136	0.000842	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000136	0.00084	CbGpPWpGaD
Regorafenib—Rash—Methotrexate—ankylosing spondylitis	0.000135	0.00196	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000135	0.00196	CcSEcCtD
Regorafenib—Headache—Methotrexate—ankylosing spondylitis	0.000134	0.00195	CcSEcCtD
Regorafenib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000133	0.000825	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000133	0.000823	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000133	0.000821	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000132	0.000816	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1RN—ankylosing spondylitis	0.000132	0.000815	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	0.000131	0.000813	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000131	0.000809	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—TLR4—ankylosing spondylitis	0.00013	0.000808	CbGpPWpGaD
Regorafenib—RAF1—Disease—B3GNT2—ankylosing spondylitis	0.00013	0.000804	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-C—ankylosing spondylitis	0.00013	0.000803	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	0.000129	0.000801	CbGpPWpGaD
Regorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000128	0.00079	CbGpPWpGaD
Regorafenib—Nausea—Methotrexate—ankylosing spondylitis	0.000127	0.00184	CcSEcCtD
Regorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000127	0.000788	CbGpPWpGaD
Regorafenib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000127	0.000787	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000126	0.000783	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000126	0.000781	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000126	0.000779	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—CRP—ankylosing spondylitis	0.000125	0.000773	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000123	0.000765	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—CRP—ankylosing spondylitis	0.000123	0.00076	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1RN—ankylosing spondylitis	0.000121	0.000749	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—TLR4—ankylosing spondylitis	0.00012	0.000742	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000119	0.00074	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1RN—ankylosing spondylitis	0.000119	0.000735	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	0.000118	0.000733	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	0.000118	0.000728	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000117	0.000726	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000117	0.000724	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	0.000117	0.000722	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—CRP—ankylosing spondylitis	0.000116	0.000721	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	0.000116	0.000719	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD79A—ankylosing spondylitis	0.000116	0.000716	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000115	0.000714	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—TNF—ankylosing spondylitis	0.000115	0.000713	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000114	0.000704	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-C—ankylosing spondylitis	0.000114	0.000703	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000113	0.000701	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000113	0.000701	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1RN—ankylosing spondylitis	0.000113	0.000698	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	0.000112	0.000696	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000112	0.000694	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—B3GNT2—ankylosing spondylitis	0.000112	0.000692	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—B3GNT2—ankylosing spondylitis	0.000112	0.000692	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000112	0.000692	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—TLR4—ankylosing spondylitis	0.000112	0.000691	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	0.000111	0.000689	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000107	0.000659	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD79A—ankylosing spondylitis	0.000106	0.000657	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000106	0.000655	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000106	0.000654	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000105	0.000653	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000105	0.000652	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	0.000105	0.000648	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD79A—ankylosing spondylitis	0.000104	0.000646	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-C—ankylosing spondylitis	0.000104	0.000643	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000102	0.000633	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	0.000102	0.000631	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000101	0.000627	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	0.000101	0.000627	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	0.0001	0.000621	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD79A—ankylosing spondylitis	9.89e-05	0.000613	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	9.87e-05	0.000611	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1RN—ankylosing spondylitis	9.87e-05	0.000611	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	9.77e-05	0.000605	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	9.77e-05	0.000605	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	9.49e-05	0.000587	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1A—ankylosing spondylitis	9.48e-05	0.000587	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD40LG—ankylosing spondylitis	9.43e-05	0.000584	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.39e-05	0.000581	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CRP—ankylosing spondylitis	9.32e-05	0.000577	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTGER4—ankylosing spondylitis	9.1e-05	0.000564	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1RN—ankylosing spondylitis	9.03e-05	0.000559	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTGER4—ankylosing spondylitis	9.02e-05	0.000558	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-B—ankylosing spondylitis	8.97e-05	0.000555	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—TLR4—ankylosing spondylitis	8.94e-05	0.000554	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	8.89e-05	0.00055	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1A—ankylosing spondylitis	8.7e-05	0.000539	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD79A—ankylosing spondylitis	8.66e-05	0.000536	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD40LG—ankylosing spondylitis	8.65e-05	0.000536	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1A—ankylosing spondylitis	8.55e-05	0.000529	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD40LG—ankylosing spondylitis	8.5e-05	0.000526	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTGER4—ankylosing spondylitis	8.36e-05	0.000517	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HLA-A—ankylosing spondylitis	8.31e-05	0.000514	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-B—ankylosing spondylitis	8.23e-05	0.00051	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	8.21e-05	0.000508	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1A—ankylosing spondylitis	8.11e-05	0.000502	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—TNF—ankylosing spondylitis	8.11e-05	0.000502	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	8.09e-05	0.000501	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-B—ankylosing spondylitis	8.08e-05	0.000501	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD40LG—ankylosing spondylitis	8.07e-05	0.000499	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	8.04e-05	0.000498	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP3—ankylosing spondylitis	7.98e-05	0.000494	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CRP—ankylosing spondylitis	7.92e-05	0.000491	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD79A—ankylosing spondylitis	7.92e-05	0.000491	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTGER4—ankylosing spondylitis	7.79e-05	0.000482	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	7.77e-05	0.000481	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-B—ankylosing spondylitis	7.67e-05	0.000475	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	7.65e-05	0.000474	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-A—ankylosing spondylitis	7.63e-05	0.000472	CbGpPWpGaD
Regorafenib—BRAF—Disease—HLA-A—ankylosing spondylitis	7.6e-05	0.00047	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—TLR4—ankylosing spondylitis	7.6e-05	0.00047	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP3—ankylosing spondylitis	7.54e-05	0.000467	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—MMP3—ankylosing spondylitis	7.52e-05	0.000466	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-A—ankylosing spondylitis	7.49e-05	0.000464	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	7.29e-05	0.000451	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CRP—ankylosing spondylitis	7.28e-05	0.00045	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	7.25e-05	0.000449	CbGpPWpGaD
Regorafenib—KIT—Immune System—CRP—ankylosing spondylitis	7.15e-05	0.000442	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-A—ankylosing spondylitis	7.11e-05	0.00044	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1A—ankylosing spondylitis	7.1e-05	0.00044	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	7.09e-05	0.000439	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD40LG—ankylosing spondylitis	7.06e-05	0.000437	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HLA-A—ankylosing spondylitis	7.04e-05	0.000436	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	7e-05	0.000433	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—TLR4—ankylosing spondylitis	6.98e-05	0.000432	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—TNF—ankylosing spondylitis	6.97e-05	0.000432	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—B3GNT2—ankylosing spondylitis	6.96e-05	0.000431	CbGpPWpGaD
Regorafenib—KIT—Disease—HLA-A—ankylosing spondylitis	6.92e-05	0.000428	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	6.89e-05	0.000427	CbGpPWpGaD
Regorafenib—KIT—Immune System—TLR4—ankylosing spondylitis	6.85e-05	0.000424	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CRP—ankylosing spondylitis	6.78e-05	0.00042	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CRP—ankylosing spondylitis	6.76e-05	0.000419	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-B—ankylosing spondylitis	6.72e-05	0.000416	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HLA-A—ankylosing spondylitis	6.56e-05	0.000406	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	6.55e-05	0.000405	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—TLR4—ankylosing spondylitis	6.5e-05	0.000403	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1A—ankylosing spondylitis	6.5e-05	0.000402	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	6.48e-05	0.000402	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP3—ankylosing spondylitis	6.48e-05	0.000401	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD40LG—ankylosing spondylitis	6.46e-05	0.0004	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP3—ankylosing spondylitis	6.42e-05	0.000398	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	6.39e-05	0.000395	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.24e-05	0.000386	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-A—ankylosing spondylitis	6.22e-05	0.000385	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-B—ankylosing spondylitis	6.14e-05	0.00038	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CRP—ankylosing spondylitis	6.09e-05	0.000377	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—TNF—ankylosing spondylitis	5.97e-05	0.000369	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP3—ankylosing spondylitis	5.95e-05	0.000368	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CRP—ankylosing spondylitis	5.94e-05	0.000368	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	5.9e-05	0.000365	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	5.89e-05	0.000365	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	5.84e-05	0.000362	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	5.84e-05	0.000362	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TLR4—ankylosing spondylitis	5.69e-05	0.000353	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-A—ankylosing spondylitis	5.69e-05	0.000353	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP3—ankylosing spondylitis	5.55e-05	0.000343	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	5.53e-05	0.000343	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CRP—ankylosing spondylitis	5.43e-05	0.000336	CbGpPWpGaD
Regorafenib—RAF1—Disease—HLA-A—ankylosing spondylitis	5.26e-05	0.000325	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	5.26e-05	0.000325	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	5.23e-05	0.000324	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TLR4—ankylosing spondylitis	5.21e-05	0.000322	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	5.13e-05	0.000318	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	4.98e-05	0.000309	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	4.82e-05	0.000298	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	4.79e-05	0.000297	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—ankylosing spondylitis	4.78e-05	0.000296	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP3—ankylosing spondylitis	4.44e-05	0.000275	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3.16e-05	0.000196	CbGpPWpGaD
